Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

The allogeneic dilemma

Bone Marrow Transplantation volume 40, pages 1123–1128 (2007)Cite this article

Abstract

The place of allogeneic SCT in the management of multiple myeloma remains controversial. Although it may induce long-term clinical and molecular remissions, the very high transplant-related toxicity after a myeloablative preparative regimen has limited its role to younger patients as first-line treatment option. Even with this limited indication, toxic death rate related to infections and GVHD is considered too high and this strategy has been almost abandoned. Reduced intensity conditioning (RIC) regimens look promising, as the transplant-related mortality is low even with matched unrelated donors and can be considered for older patients up to the age of 65 years. However when used in patients with a high tumor burden or with chemo-resistant disease, the immunologic effect of the graft is not sufficient to avoid relapses. Therefore, RIC allotransplantation is currently used after tumor mass reduction with high-dose therapy followed by autologous SCT. A recently published Italian study shows that this strategy induces better event-free survival than double autologous SCT due to a reduced relapse rate. The questions raised by this encouraging result are discussed in this paper.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Corradini P, Voena C, Tarella C, Astolfi M, Ladetto M, Palumbo A et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999; 17: 208–215.

    Article  CAS  Google Scholar 

  2. Gahrton G, Tura S, Ljungman P, Blade J, Brandt L, Cavo M et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995; 13: 1312–1322.

    Article  CAS  Google Scholar 

  3. Bensinger WI, Buckner CD, Anasetti C, Clift R, Storb R, Barnett T et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996; 88: 2787–2793.

    CAS  PubMed  Google Scholar 

  4. Mehta J . Allogeneic hematopoietic stem cell transplantation in myeloma. In: Mehta J, Singhal S (eds). Myeloma Editions. Martin Dunitz: London, 2002; pp 349–365.

    Google Scholar 

  5. Bjorkstrand BB, Ljungman P, Svensson H, Hermans J, Alegre A, Apperley J et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996; 88: 4711–4718.

    CAS  PubMed  Google Scholar 

  6. Couban S, Stewart AK, Loach D, Panzarella T, Meharchand J . Autologous and allogeneic transplantation for multiple myeloma. Bone Marrow Transplant 1997; 19: 783–789.

    Article  CAS  Google Scholar 

  7. Gahrton G, Svensson H, Cavo M, Apperly J, Bacigalupo A, Björkstrand B et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–1993 and 1994–1998 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001; 113: 209–216.

    Article  CAS  Google Scholar 

  8. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of the Phase III US Intergroup trial S4321. J Clin Oncol 2006; 24: 929–936.

    Article  CAS  Google Scholar 

  9. Alyea E, Weller E, Schlossman R, Canning C, Webb I, Doss D et al. T-cell depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood 2001; 98: 934–939.

    Article  CAS  Google Scholar 

  10. Lokhorst HM, Segeren CM, Verdonck LF, van der Holt B, Raymakers R, van Oers MH et al. Partially T-cell depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study Hovon 24 MM. J Clin Oncol 2003; 21: 1728–1733.

    Article  Google Scholar 

  11. Mehta J, Tricot G, Jagannath S, Ayers D, Singhal S, Siegel D et al. Salvage autologous or allogeneic transplantation for multiple myeloma refractory or relapsing after a first autograft. Bone Marrow Transplant 1998; 21: 887–892.

    Article  CAS  Google Scholar 

  12. Libura J, Hoffman T, Passweg J, Gregor M, Favre G, Tichelli A et al. Graft-versus myeloma after withdrawal of immunosuppression following allogeneic peripheral stem cell transplantation. Bone Marrow Transplant 1999; 24: 925–927.

    Article  CAS  Google Scholar 

  13. Le Blanc R, Montming-Metivier S, Belanger R, Busque L, Fish D, Roy DC et al. Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect. Bone Marrow Transplant 2001; 28: 841–848.

    Article  CAS  Google Scholar 

  14. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B . Graft-versus myeloma effect: proof of principle. Blood 1996; 87: 1196–1198.

    CAS  PubMed  Google Scholar 

  15. Verdonck L, Lokhorst H, Dekker A, Nieuwenhuis HK, Petersen EJ . Graft versus myeloma effect in two cases. Lancet 1996; 347: 800–801.

    Article  CAS  Google Scholar 

  16. Aschan J, Lonnquist B, Ringden O, Kumlien G, Gahrton G . Graft-versus myeloma effect. Lancet 1996; 348: 346.

    Article  CAS  Google Scholar 

  17. Collins RH, Shpilberg O, Drobyski Wr, Porter DL, Giralt S, Champlin R et al. Donor lymphocyte infusions in 140 patients with relapsed malignancies after allogeneic bone marrow transplantation. J Clin Oncol 1997; 22: 835–843.

    Google Scholar 

  18. Lokhorst HM, Wu K, Verdonck LF, Laterveer LL, van de Donk NW, van Oers MH et al. The occurrence of graft versus host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004; 103: 4362–4364.

    Article  CAS  Google Scholar 

  19. Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 2002; 30: 367–373.

    Article  CAS  Google Scholar 

  20. Einsele H, Schafer HJ, Hebart H, Bader P, Meisner C, Plasswilm L et al. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol 2003; 121: 411–418.

    Article  Google Scholar 

  21. Peggs KS, Mackinnon S, Williams CD, D’Sa S, Thuraisundaram D, Kyriakou C et al. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus tumor activity. Biol Blood Marrow Transplant 2003; 9: 257–265.

    Article  Google Scholar 

  22. Perez-Simon JA, Martino R, Alegre A, Tomás JF, De Leon A, Caballero D et al. Chronic but not acute graft versus host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. Br J Haematol 2003; 121: 104–108.

    Article  Google Scholar 

  23. Mohty M, Boiron JM, Damaj G, Michallet AS, Bay JO, Faucher C et al. Graft-versus myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 34: 77–87.

    Article  CAS  Google Scholar 

  24. Gerull S, Goerner M, Benner A . Long-term outcome of non myeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplant 2005; 36: 963–969.

    Article  CAS  Google Scholar 

  25. Kroger N, Sayer HG, Schwerdtfeger R, Kiehl M, Nagler A, Renges H et al. Unrelated stem cell transplantation in reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002; 100: 3919–3924.

    Article  CAS  Google Scholar 

  26. Crawley C, Lalancette M, Szydlo R, Gilleece M, Peggs K, Mackinnon S et al. Outcomes of reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005; 105: 4532–4539.

    Article  CAS  Google Scholar 

  27. Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM et al. Graft-versus-host disease after non myeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756–762.

    Article  CAS  Google Scholar 

  28. Kroger N, Perez-Simon JA, Myint H, Klingemann H, Shimoni A, Nagler A et al. Relapse to prior autograft and chronic graft-versus host disease are the strongest prognostic factors for outcome of melphalan/fludarabine based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2004; 10: 698–708.

    Article  Google Scholar 

  29. Crawley C, Iacobelli S, Björkstrand B, Apperley JF, Niederwieser D, Gahrton G . Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007; 109: 3588–3594.

    Article  CAS  Google Scholar 

  30. Badros A, Barlogie B, Siegel E, Cottler-Fox M, Zangari M, Fassas A et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after non-myeloablative conditioning. J Clin Oncol 2002; 20: 1295–1303.

    Article  Google Scholar 

  31. Kroger N, Schwerdtfeger R, Kiehl M, Sayer HG, Renges H, Zabelina T et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002; 100: 755–760.

    Article  CAS  Google Scholar 

  32. Maloney D, Molina A, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 101: 3447–3454.

    Article  Google Scholar 

  33. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. Single versus double autologous stem-cell transplantation for multiple myeloma. New Engl J Med 2003; 349: 2495–2502.

    Article  CAS  Google Scholar 

  34. Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM 99–03 trial) with tandem autologous stem cell transplantation (IFM 99–04 trial) in high-risk de novo multiple myeloma. Blood 2006; 107: 3474–3480.

    Article  CAS  Google Scholar 

  35. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F et al. A comparison of allografting with autografting for newly diagnosed myeloma. New Engl J Med 2007; 356: 1110–1120.

    Article  CAS  Google Scholar 

  36. Moreau P, Garban F, Facon T, Hulin C, Attal M, Benbouker L et al. Long-term and updated results of the IFM9903 and IFM9904 protocols comparing autologous followed by RIC-allogeneic transplantation and double transplant in high-risk de novo multiple myeloma. Bone Marrow Transplant 2007; 39 (Suppl 1): S24–S25; abstract.

    Google Scholar 

  37. Kroger N, Schilling G, Einsele H, Liebisch P, Shimoni A, Nagler A et al. Deletion of chromosome 13q14 detected by fluorescence in situ hibridization as prognostic factor following allogeneic dose-reduced stem cell transplantation in patients with multiple myeloma. Blood 2006; 103: 4056–4061.

    Article  Google Scholar 

  38. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108: 3289–3294.

    Article  CAS  Google Scholar 

  39. Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Geneviève F, Zandecki M et al. Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97: 1566–1571.

    Article  CAS  Google Scholar 

  40. Tricot G, Spencer T, Sawyer J, Spoon D, Desikan R, Fassas A et al. Predicting long-term (⩾5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol 2002; 116: 211–217.

    Article  Google Scholar 

  41. Kroger N, Shimoni A, Zagrivnaja M, Ayuk F, Lioznov M, Schieder H et al. Low-dose thalidomide and donor lymphocyte infusions as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 2004; 104: 3361–3363.

    Article  Google Scholar 

  42. Bruno B, Patriarca F, Sorasio R, Mattei D, Montefusco V, Peccatori J et al. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. Haematologica 2006; 91: 837–839.

    CAS  PubMed  Google Scholar 

  43. Tosi P, Zamagni E, Cangini B, Tacchetti P, Perrone G, Ceccolini M et al. Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation. Ann Hematol 2006; 85: 549–558.

    Article  Google Scholar 

  44. Van de Donk NW, Kroger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood 2006; 107: 3415–3416.

    Article  CAS  Google Scholar 

  45. Kroger N, Zabelina T, Ayuk F, Atanackovic D, Schieder H, Renges H et al. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol 2006; 34: 770–775.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Centre Hospitalier Universitaire Hôtel-Dieu, Nantes, France

    J-L Harousseau

Authors
  1. J-L Harousseau
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J-L Harousseau.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harousseau, JL. The allogeneic dilemma. Bone Marrow Transplant 40, 1123–1128 (2007). https://doi.org/10.1038/sj.bmt.1705810

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705810

Keywords

This article is cited by

Search

Advanced search

Quick links